Humanwell Healthcare (600079.SH): HW091077 tablets have entered Phase II clinical trial research.

Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd. (hereinafter referred to as "Research Institute Limited"), recently disclosed the registration information of the II phase clinical trial of HW091077 tablets on the National Medical Products Administration Drug Clinical Trial Registration and Information Disclosure Platform. HW091077 tablets received the approval notice of drug clinical trial from the National Medical Products Administration in October 2023. The applicant for the clinical trial is Wuhan Renfu Innovative Drug Development Center Co., Ltd. (hereinafter referred to as "Innovative Drug Development Center"), and the approved indication for the clinical trial is for the treatment of patients with refractory chronic cough. In December 2025, the HW091077 tablet project was transferred from Innovative Drug Development Center to Research Institute Limited. Recently, the indication for refractory chronic cough of HW091077 tablets entered the II phase clinical trial research. According to the Insight database, there is currently no drug on the market in China with the same target and indication, with 2 companies in the III phase clinical stage and 5 companies in the II phase clinical stage. As of now, the cumulative research and development investment in this project is approximately RMB 58 million.